NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
IMBRUVICA (ibrutinib) by AbbVie is protein kinase inhibitors [moa]. Approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma. First approved in 2018.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMBRUVICA (ibrutinib) is an oral small-molecule protein kinase inhibitor that irreversibly blocks Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling. It treats a broad spectrum of hematologic malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and several other B-cell lymphomas, as well as non-malignant conditions like chronic graft-versus-host disease and chronic spontaneous urticaria. The drug works by selectively inhibiting BTK and related kinases, disrupting survival and proliferation signals in malignant and autoreactive B cells.
Peak10.3 years to LOE
IMBRUVICA is at peak commercial lifecycle with $2.4B in spending, supporting a mature commercial organization with significant medical affairs and sales infrastructure.
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on IMBRUVICA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.